Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Abraxane prolongs survival in metastatic breast cancer

Abraxane prolongs survival in metastatic breast cancer

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

Combination of two chemotherapy drugs shows promise against recurrent gynecologic cancers

Combination of two chemotherapy drugs shows promise against recurrent gynecologic cancers

3-drug chemotherapy combo increases organ preservation in patients with larynx cancer

3-drug chemotherapy combo increases organ preservation in patients with larynx cancer

New therapeutic approaches to castrate resistant prostate cancer

New therapeutic approaches to castrate resistant prostate cancer

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Algeta completes phase II trial with Alpharadin for treating bone metastases in advanced prostate cancer

Algeta completes phase II trial with Alpharadin for treating bone metastases in advanced prostate cancer

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib just as effective as chemotherapy for lung cancer

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

OncoGenex achieves key regulatory milestone for lead product candidate

OncoGenex achieves key regulatory milestone for lead product candidate

Anticancer drug triggers nanoparticle formation, improves stability in vivo

Anticancer drug triggers nanoparticle formation, improves stability in vivo

Adding Taxotere to chemotherapy regimen improves survival in early breast cancer

Adding Taxotere to chemotherapy regimen improves survival in early breast cancer

Trastuzumab-DM1 - a 'smart bomb' for breast cancer treatment

Trastuzumab-DM1 - a 'smart bomb' for breast cancer treatment

OncoGenex Pharmaceuticals' OGX-011 granted FDA fast track status

OncoGenex Pharmaceuticals' OGX-011 granted FDA fast track status

FDA lifts clinical hold on Genta's Tesetaxel

FDA lifts clinical hold on Genta's Tesetaxel

Cetuximab and chemotherapy combination proves safe, effective for head and neck cancer patients

Cetuximab and chemotherapy combination proves safe, effective for head and neck cancer patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.